We’d love to hear your feedback on this activity. It helps us to continually improve our products.
touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens. Question What are the current unmet educational needs in the treatment of metastatic […]
touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens. Questions What is the rationale for the combination of immune checkpoint inhibitors and […]
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood clots form in small blood vessels throughout the body. In this interview, Dr Cataland discusses […]
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
touchONCOLOGY spoke to Ken Kato (Tokyo, Japan) to discuss his presentation on the JCOG1109 NExT study, a randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer. Questions What are the limitations of cisplatin plus 5-fluorouracil neoadjuvant treatment as the standard of […]
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss what we have learned from the COVID-19 pandemic, how this has impacted the care of cancer patients and what we can do to move forward. Questions What was the impact of the COVID-19 pandemic on […]
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss the impact of immune checkpoint inhibitors on the treatment of bladder cancer, and other exciting therapeutic advances. Questions How have immune checkpoint inhibitors changed the treatment landscape for bladder cancer? (00:35-03:35) What […]
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss his highlights from the 2022 conference. Questions Could you tell us a little about the this year’s EAU Section of Oncological Urology (ESOU22) and how well it went? (00:34-01:42) What were this […]
Get the latest clinical insights from touchONCOLOGY